Review Paper on Parkinsons Disease

A small group of researchers gathered at the annual Movement Disorders Society meeting in Paristo discuss forming a collaboration focused on the genetics of Parkinson's disease (PD). This meetingled to the creation of the International Parkinson Disease Genomics Consortium (IPDGC), whichemphasizes trust, collaboration, and minimal bureaucracy. Since its founding, the IPDGC hasexpanded significantly, now including over 100 scientists worldwide. The group's focus hasbroadened to encompass large-scale clinical and functional studies of PD.Recently, the IPDGC hasinitiated major research projects in East Asia and Africa and is collaborating with significant effortsin India and South America. In this overview, we summarize the accomplishments of the IPDGCover the past decade in PD genomics and outline our research priorities and future directions for thenext ten years.Parkinson’s disease (PD) is increasingly recognized as a complex condition that includes variousclinical subtypes, genetic factors, and environmental influences. In addition to the well-known motorsymptoms, patients often experience non-motor issues like sleep disturbances, loss of smell,constipation, and depression early on. As the disease progresses, cognitive decline and autonomicdysfunction become more prominent.Key mechanisms driving PD include the misfolding andaggregation of a protein called alpha-synuclein, mitochondrial dysfunction, impaired proteinclearance, neuroinflammation, and oxidative stress. This complex pathology also involves multipleneurotransmitter systems, which explains the diverse symptoms of PD and suggests that treatmentmay go beyond standard dopamine therapies.One major challenge in developing newneuroprotective treatments is the absence of reliable biomarkers to track disease progression. Currentresearch is exploring immunotherapies targeting toxic forms of alpha-synuclein, as well as strategiesto enhance protein clearance and prevent aggregation.